other material
confidence high
sentiment neutral
materiality 0.50
Leap Therapeutics completes Part A enrollment (33 pts) in Phase 2 DeFianCe study of DKN-01 for colorectal cancer
CYPHERPUNK TECHNOLOGIES INC.
- Part A enrolled 33 patients with advanced colorectal cancer; study is randomized, open-label, multicenter.
- Part B is planned as a 130-patient randomized controlled trial; primary endpoint is progression-free survival.
- Initial data from the study expected in mid-2023.
- Secondary endpoints include overall response rate, duration of response, and overall survival.